Premium
Expression of matricellular protein CCN1 in the tumor stroma is required for melanoma metastasis
Author(s) -
Leask Andrew,
Postovit Lynne,
Quensel Katherine,
Hutchenreuther James
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.808.3
Subject(s) - matricellular protein , stroma , metastasis , cancer research , melanoma , tumor progression , biology , desmoplasia , tumor microenvironment , periostin , cyr61 , extracellular matrix , cancer , pathology , ctgf , immunohistochemistry , medicine , immunology , microbiology and biotechnology , growth factor , tumor cells , biochemistry , genetics , receptor
Metastatic melanoma has an extremely poor prognosis. BRAF inhibitors are used to treat a subset of patients but eventually patients acquire resistance to this therapy. An increasing body of evidence suggests that an activated tumor stroma is responsible for the acquisition of resistance to chemotherapy. Herein, we find that he secreted matricellular protein cyr61(CCN1) is overexpressed in human melanoma in a fashion that correlates negatively with clinical outcome, positively with the extent of tumor stroma development and not at all with BRAF mutational status. We have used a fibroblast‐specific type I collagen promoter‐driven cre recombinase that is tamoxifen dependent to generate C57BL6 mice deleted or not for CCN1 in fibroblasts. CCN1‐deficicent mice display progressive reduction in skin thickness. When injected subcutaneously, B16(F10) cells show reduced metastasis to the lung. Tumor growth is unaffected. This phenotype is linked with reduction in expression of collagen‐modifying enzymes LOX, P4H and PLOD2 as well as a decrease in insoluble collagen protein expression as visualized by a hydroxyproline assay and by trichrome staining. Type I collagen mRNA expression is unaffected.. Thus, CCN1 is required for proper induction of a tumor stroma and hence for metastasis and thus should be further evaluated as a possible therapeutic target for BRAF inhibitor‐resistant melanoma. Support or Funding Information CIHR, Canadian Cancer Society